Cardinal Health extended CVS deal: Cardinal Health stock sits 8.30 percent below its high
Published on 10/09/2026 at 16:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Cardinal Health extended its pharmaceutical distribution agreements with CVS Health through June 30, 2032.
- Fiscal 2026 fourth-quarter revenue rose 6.00 percent to USD 63.70 billion, while GAAP diluted earnings per share increased 70.00 percent to USD 1.70.
- Cardinal Health stock was EUR 211.85 at Lang & Schwarz on October 9, 2026, down 0.61 percent from the prior close.
- Nineteen analysts carry a Moderate Buy consensus with an average twelve-month target of USD 266.56.
Cardinal Health (ISIN US14149Y1082) was trading at EUR 211.85 at Lang & Schwarz on October 9, 2026 at 4:42 p.m. CEST, down 0.61 percent versus the prior close of EUR 213.15. On October 1, 2026, Cardinal Health announced a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 30, 2032. On the NYSE, the stock was last at USD 236.86 at 10:50 a.m. EDT, 8.30 percent below its 52-week high of USD 258.30.
What does the CVS extension change?
The agreement keeps Cardinal Health's existing pharmaceutical distribution scope for CVS Health through June 30, 2032. El Fondo reported on October 1, 2026, that Cardinal Health reaffirmed fiscal 2027 non-GAAP earnings per share guidance of USD 12.40-12.60, representing 13.00 to 15.00 percent growth.
Three results milestones
On April 30, 2026, Cardinal Health reported third-quarter fiscal 2026 revenue of USD 60.90 billion and raised its outlook, according to its Newsroom. On August 11, 2026, fourth-quarter revenue increased 6.00 percent to USD 63.70 billion, while GAAP diluted earnings per share increased 70.00 percent to USD 1.70, with a USD 0.31 one-time tariff impact disclosed in the release.
The October 1 CVS announcement was the latest of the three milestones and paired contract continuity with the fiscal 2027 earnings outlook. That combination gives the distribution business a dated customer commitment while management expects adjusted earnings per share of USD 12.40-12.60.
Analyst target remains above the price
MarketBeat reported on October 9, 2026, that nineteen analysts held a Moderate Buy consensus, with sixteen Buy ratings and three Hold ratings. The average twelve-month target was USD 266.56, which lies 12.54 percent above the NYSE price of USD 236.86.
Upcoming dates for Cardinal Health
The next dated items are October 15, 2026, when a quarterly dividend of USD 0.5158 per share is scheduled for payment, according to MarketBeat, and November 5, 2026, when Cardinal Health plans to report fiscal 2027 first-quarter results.
Cardinal Health stock stays below its high
At Lang & Schwarz, Cardinal Health was trading at EUR 211.85 on October 9, 2026 at 4:42 p.m. CEST, down 0.61 percent versus the EUR 213.15 prior close dated October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Cardinal Health stock.
Cardinal Health stock facts
- Company: Cardinal Health, Inc.
- ISIN: US14149Y1082
- Ticker: CAH
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 9, 2026, 4:42 p.m. CEST): EUR 211.85
- Change versus prior close: minus 0.61 percent
- Prior close Lang & Schwarz (October 8, 2026): EUR 213.15
- Market capitalization: USD 55.5 billion (as of October 9, 2026)
- 52-week range: USD 151.87-258.30 (as of October 9, 2026)
- Sector / Industry: Healthcare / Medical Distribution
- Index membership: S&P 500
- Next earnings date: November 5, 2026
Market context: Market report S&P 500.
